

DAFTAR PUSTAKA

1. Liang F, Wang Y. Coronary heart disease and atrial fibrillation: A vicious cycle. *Am J Physiol Heart Circ Physiol*. 2021 Jan 1;320(1).
2. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. *J Cell Physiol*. 2019 Oct 1;234(10):16812–23.
3. Sucato V, Coppola G, Manno G, Vadalà G, Novo G, Corrado E, et al. Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments. *Curr Probl Cardiol*. 2023 Aug 1;48(8).
4. Ralapanawa U, Sivakanesan R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: A narrative review. *J Epidemiol Glob Health*. 2021 Jun 1;11(2):169–77.
5. Rachmawati C, Martini S, Artanti KD. Analisis Faktor Risiko Modifikasi Penyakit Jantung Koroner Di RSUD Haji Surabaya Tahun 2019. *Media Gizi Kesmas*. 2021 Jun 1;10(1):47–55.
6. Aditya Defran D, Amadi Putra A, Vionanda D, Tessy Octavia Mukhti dan. Classification of Coronary Heart Disease at Semen Padang Hospital using Algorithm Classification And Regression Trees (CART). *UNP Journal of Statistics and Data Science*. 2023 Nov 30;1(5):399–404.
7. Nakagawa T, Mazzali M, Kang DH, Sánchez-Lozada LG, Herrera-Acosta J, Johnson RJ. Uric acid - A uremic toxin? *Blood Purif*. 2006 Dec;24(1):67–70.
8. Kim JY, Seo C, Pak H, Lim H, Chang TI. Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study. *J Korean Med Sci*. 2023;38(38).

9. Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, et al. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality over 20 Years. *Hypertension*. 2020 Feb 1;75(2):302–8.
10. Prasetyo DH, Nasution SA, Alwi I, Abdullah M. Correlation between Serum Uric Acid Level and Severity of Coronary Artery Stenosis in Patients with Acute Coronary Syndrome. *Majalah Kedokteran Bandung*. 2021 Mar 20;53(1):1–6.
11. Rahimi-Sakak F, Maroofi M, Rahmani J, Bellissimo N, Hekmatdoost A. Serum uric acid and risk of cardiovascular mortality: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. *BMC Cardiovasc Disord*. 2019 Oct 15;19(1).
12. Lim SS, Yang YL, Chen SC, Wu CH, Huang SS, Chan WL, et al. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. *Atherosclerosis*. 2020 Mar 1;297:40–6.
13. Liu X, Xu X, Shang R, Chen Y. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. *Nitric Oxide*. 2018 Aug 1;78:113–20.
14. Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. *Redox Biol*. 2021 Oct 1;46.
15. Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, et al. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. *Mayo Clin Proc*. 2021 Oct 1;96(10):2660–70.
16. Stone NJ, Greenland P, Grundy SM. Statin Usage in Primary Prevention—Comparing the USPSTF Recommendations With the

AHA/ACC/Multisociety Guidelines. JAMA Cardiol. 2022 Oct 1;7(10):997– 9.

17. Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A. The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Meta-analysis. *Curr Med Chem*. 2023 Feb 7;31(13):1726–39.
18. Palikhey A, Lodh A, Shrestha J, Karki M, Shrivastava AK. An effect of statin on serum uric acid in patients with dyslipidemia at a tertiary care hospital. *Endocrine and Metabolic Science*. 2023 Dec 1;13.
19. Garcia-Gil M, Comas-Cufí M, Ramos R, Martí R, Alves-Cabratosa L, Parramon D, et al. Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study. *J Cardiovasc Pharmacol Ther*. 2019 Nov 1;24(6):542–50.
20. Lin GL, Lin HC, Lin HL, Keller JJ, Wang LH. Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study. *Front Pharmacol*. 2023;14.
21. Zheng D, Liang Q, Zeng F, Mai Z, Cai A, Qiu R, et al. Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. *Lipids Health Dis*. 2015 May 2;14(1).
22. Nishiyama Y, Ueda M, Otsuka T, Katsura K ichiro, Abe A, Nagayama H, et al. Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in Ischemic stroke patients. *J Atheroscler Thromb*. 2011;18(2):131–7.
23. Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GYH, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. *Sci Rep*. 2015 May 13;5(1):1–8.
24. Kibel A, Lukinac AM, Dambic V, Juric I, Relatic KS. Oxidative Stress in Ischemic Heart Disease. *Oxid Med Cell Longev*. 2020;2020:6627144.

25. Sucato V, Madaudo C, Galassi AR. Classification, Diagnosis, and Treatment of Coronary Microvascular Dysfunction. *J Clin Med*. 2022 Aug 1;11(15):4610.
26. Butnariu LI, Florea L, Badescu MC, Țarcă E, Costache II, Gorduza EV. Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component? *Life*. 2022 Jun 1;12(6).
27. Brown JC, Gerhardt TE, Kwon E. Risk Factors for Coronary Artery Disease [Internet]. Risk Factors in Coronary Artery Disease. StatPearls Publishing; 2023 [cited 2025 Jul 1]. p. 1–219. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554410/>
28. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics-2022 Update: A Report from the American Heart Association. *Circulation*. 2022 Feb 22;145(8):E153–639.
29. Duggan JP, Peters AS, Trachiotis GD, Antevil JL. Epidemiology of Coronary Artery Disease. *Surgical Clinics of North America*. 2022 Jun 1;102(3):499–516.
30. Virani SS, Newby LK, Arnold S V., Bittner V, Brewer LPC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023 Aug 29;148(9):E9–119.
31. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association. *Circulation*. 2024 Feb 20;149(8):E347–913.

32. WCOTROCHADIC T. Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary. *Biomedical and Environmental Sciences*. 2023 Aug 1;36(8):669–701.
33. Ohira T, Eguchi E, Hayashi F, Kinuta M, Imano H. Epidemiology of cardiovascular disease in Japan: An overview study. *J Cardiol*. 2024 Mar 1;83(3):191–200.
34. Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. *Biomedicines*. 2022 Aug 1;10(8).
35. Crea F, Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular Dysfunction. *Circulation Journal*. 2022;86(9):1319–28.
36. Jia S, Liu Y, Yuan J. Evidence in Guidelines for Treatment of Coronary Artery Disease. *Adv Exp Med Biol*. 2020;1177:37–73.
37. Zi Zhao, Su Cheng, Di Zhao, Wu Guo, Ki Deng, Ye Li. Serum uric acid and endothelial dysfunction: A clinical survey. *Clin Lab*. 2021;67(7).
38. En Martínez-Quintana, Fu Rodríguez-González, Ma Morales-Suárez-Varela, Di Fernández-Bergés. Uric acid as a cardiovascular risk factor in heart disease. *Int J Environ Res Public Health*. 2023;20(4):3087.
39. Si Pahlevan, Ra Ti Rasekhi. Role of uric acid in cardiovascular disease: Focus on arterial stiffness, endothelial dysfunction, and inflammation. *J Clin Lab Anal*. 2024;38(4):1–4.
40. Iai- AP, Clement L. Terapi Antiangina untuk Angina Pectoris Stabil. *Cermin Dunia Kedokteran*. 2022 Dec 1;49(12):702–7.
41. Fu B, Wei X, Lin Y, Chen J, Yu D. Pathophysiologic Basis and Diagnostic Approaches for Ischemia With Non-obstructive Coronary Arteries: A Literature Review. *Front Cardiovasc Med*. 2022 Mar 17;9.

42. Shao C, Wang J, Tian J, Tang Y da. Coronary Artery Disease: From Mechanism to Clinical Practice. *Adv Exp Med Biol*. 2020;1177:1–36.
43. Saraste A, Knuuti J. ESC 2019 guidelines for the diagnosis and management of chronic coronary syndromes: Recommendations for cardiovascular imaging. *Herz*. 2020 Aug 1;45(5):409–20.
44. Bansal A, Hiwale K. Updates in the Management of Coronary Artery Disease: A Review Article. *Cureus*. 2023 Dec 17;15(12):e50644.
45. Doenst T, Thiele H, Haasenritter J, Wahlers T, Massberg S, Haverich A. Behandlung der koronaren Herzkrankheit. *Dtsch Arztebl Int*. 2022 Oct 21;119(42):716–23.
46. Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights. *Int J Mol Sci*. 2020 Jul 1;21(13):1–25.
47. Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2022 Aug 23;328(8):754–71.
48. Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment. *Int J Mol Sci*. 2022 Mar 1;23(6).
49. Waheed Y, Yang F, Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. *Korean Journal of Internal Medicine*. 2021 Nov 1;36(6):1281–93.
50. George C, Leslie SW, Minter DA. Hyperuricemia [Internet]. *Urology at a Glance*. StatPearls Publishing; 2023 [cited 2025 Jul 1]. p. 107–9. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459218/>

51. Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: Is It really asymptomatic? *Curr Opin Rheumatol*. 2020 Jan 1;32(1):71–9.
52. Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, Cicerchi C, Li N, Kuwabara M, et al. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. *Journal of Biological Chemistry*. 2019 Mar 15;294(11):4272–81.
53. Buscemi S, Buscemi C, Borzì AM, Cosentino L, Rosafio G, Randazzo C, et al. Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients with and without Type 2 Diabetes (the Diuretics and Diabetes Control Study). *Metab Syndr Relat Disord*. 2020 Mar 1;18(2):110–8.
54. Li K, Li K, Yao Q, Shui X, Zheng J, He Y, et al. The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor. *Heliyon*. 2023 May 1;9(5):e16097.
55. Zinellu A, Mangoni AA. An updated systematic review and meta-analysis of the effect of statins on asymmetric dimethylarginine. *Nitric Oxide*. 2022 Mar 1;120:26–37.
56. Muiesan ML, Agabiti-Rosei C, Painsi A, Salvetti M. Uric acid and cardiovascular disease: An update. *European Cardiology Review* . 2016;11(1).
57. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Care Res (Hoboken)*. 2020 Jun 1;72(6):744–60.
58. Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. *Curr Cardiol Rev*. 2010 Apr 22;6(2):82.

59. Banjarnahor S, Damayanti R. The Role of ADMA in Various Diseases. *Cermin Dunia Kedokteran*. 2023 Apr 3;50(4):227–33.
60. Dowsett L, Higgins E, Alanazi S, Alshuwayer NA, Leiper FC, Leiper J. ADMA: A key player in the relationship between vascular dysfunction and inflammation in atherosclerosis. *J Clin Med*. 2020 Sep 1;9(9):1–17.
61. Furuki K, Adachi H, Enomoto M, Otsuka M, Fukami A, Kumagae SI, et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: Six-year prospective study using carotid ultrasonography. *Hypertension Research*. 2008 Jun;31(6):1185–9.
62. Notsu Y, Yano S, Shibata H, Nagai A, Nabika T. Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study. *Atherosclerosis*. 2015 Mar 1;239(1):61–6.
63. Mućka S, Miodońska M, Jakubiak GK, Starzak M, Cieślak G, Stanek A. Endothelial Function Assessment by Flow-Mediated Dilation Method: A Valuable Tool in the Evaluation of the Cardiovascular System. *Int J Environ Res Public Health*. 2022 Sep 1;19(18).
64. Shao Y, Fan Y, Li J, Cao H, Liu B, Wang J, et al. Does elevated asymmetrical dimethylarginine predict major adverse cardiac events and mortality in patients after percutaneous coronary intervention? *Int J Cardiol*. 2015 Jan 15;178:188–90.
65. Ye J, Dai Y, Mao H, Zheng W, Zhang J. Prognostic value of asymmetric dimethylarginine in patients with coronary artery disease: A meta-analysis. *Nitric Oxide*. 2021 May 1;109–110:50–6.
66. Xilifu D, Abudula A, Rehemu N, Zhao L, Zhou X, Zhang X. Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction. *Exp Ther Med*. 2014 Dec 1;8(6):1683.

67. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. Effect of Statins Versus Untreated Dyslipidemia on Serum Uric Acid Levels in Patients with Coronary Heart Disease: A Subgroup Analysis of the GREEK Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. *American Journal of Kidney Diseases*. 2004 Apr 1;43(4):589–99.
68. Derosa G, Maffioli P, Reiner Ž, Simental-Mendía LE, Sahebkar A. Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. *Drugs*. 2016 Jun 1;76(9):947–56.
69. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. *Am Heart J*. 2004 Oct;148(4):635–40.
70. Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. *Diabetes Obes Metab*. 2010;12(11):983–93.
71. Jiang J, Miao W, Guo H, Tian W. Effects of rosuvastatin on serum asymmetric dimethylarginine levels and incidence of long-term cardiovascular events in patients with hyperlipidaemia and H-type hypertension. *Br J Hosp Med*. 2024 Jul 30;85(7).
72. Nurmaines Adhyka, Eka Trio Effandilus, Anggun Yulia Putri. Faktor Risiko Kejadian Penyakit Jantung Koroner di Poliklinik RSUD Solok Selatan Tahun 2022. *Jurnal Pembangunan Nagari*. 2023;8(1):93–103.
73. Kemenkes BKPK. Survei Kesehatan Indonesia (SKI) Tahun 2023 dalam Angka. 2023.
74. Deegan DF, Nigam P, Engel N. Sexual Dimorphism of the Heart: Genetics, Epigenetics, and Development. *Front Cardiovasc Med*. 2021 May 26;8:668252.

75. Regitz-Zagrosek V, Gebhard C. Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. *Nature Reviews Cardiology* 2022 20:4. 2022 Oct 31;20(4):236–47.
76. Kim HL, Kim MA. Sex Differences in Coronary Artery Disease: Insights From the KoRean wOmen’S chest pain rEgistry (KoROSE). *Korean Circ J*. 2023 Oct 1;53(10):655–76.
77. Xi Z, Qiu H, Guo T, Wang Y, Li J, Li Y, et al. Contemporary sex differences in mortality among patients with ST-segment elevation myocardial infarction: A systematic review and meta-analysis. *BMJ Open*. 2022 Mar 9;12(3).
78. Formentini FS, Zaina Nagano FE, Lopes Neto FDN, Adam EL, Fortes FS, Silva LF da. Coronary artery disease and body mass index: What is the relationship? *Clin Nutr ESPEN*. 2019 Dec 1;34:87–93.
79. Held C, Hadziosmanovic N, Aylward PE, Hagström E, Hochman JS, Stewart RAH, et al. Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy. *J Am Heart Assoc*. 2022 Feb 1;11(3).
80. Pham MHX, Christensen DM, Kristensen AT, Middelfart C, Sindet-Pedersen C, Gislason G, et al. Association of overweight and obesity with coronary risk factors and the presence of multivessel disease in patients with obstructive coronary artery disease – A nationwide registry study. *International Journal of Cardiology: Cardiovascular Risk and Prevention*. 2024 Sep 1;22.
81. Hosseini K, Mortazavi SH, Sadeghian S, Ayati A, Nalini M, Aminorroaya A, et al. Prevalence and trends of coronary artery disease risk factors and their effect on age of diagnosis in patients with established coronary artery disease: Tehran Heart Center (2005–2015). *BMC Cardiovasc Disord*. 2021 Dec 1;21(1).

82. Lima Dos Santos CC, Matharoo AS, Pinzón Cueva E, Amin U, Perez Ramos AA, Mann NK, et al. The Influence of Sex, Age, and Race on Coronary Artery Disease: A Narrative Review. *Cureus*. 2023 Oct 27;
83. Tian TT, Li H, Chen SJ, Wang Q, Tian QW, Zhang BB, et al. Serum Uric Acid as an Independent Risk Factor for the Presence and Severity of Early-Onset Coronary Artery Disease: A Case-Control Study. *Dis Markers*. 2018;2018:1236837.
84. Cui K, Song Y, Yin D, Song W, Wang H, Zhu C, et al. Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia. *J Am Heart Assoc*. 2023 Oct 17;12(20).
85. Goudhaman L, Jagadeesan AR, Sundaramoorthi S, Thotla S, Mohan SK. Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: A Pilot Study. *Rep Biochem Mol Biol*. 2021 Jul 1;10(2):302–6.
86. Huang SS, Huang WC, Tsai CT, Chen YY, Lee SH, Lu TM. Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease. *Sci Rep*. 2023 Dec 1;13(1).
87. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. *Glob Cardiol Sci Pract* [Internet]. 2014 [cited 2025 Aug 4];2014(3):291. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4352682/>
88. Cai R, Li F, Li Y, Li Y, Peng W, Zhao M, et al. Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease. *IJC Heart & Vasculature*. 2024 Aug 1;53:101434.
89. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, et al. Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy. *Coron Artery Dis*. 2014;25(4):343–8.

90. Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, et al. Comparison of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease. *Angiology*. 2014 Oct 1;65(9):788–93.

